A Phase 1, Open-Label, Safety and Immunogenicity Trial of Boost-2867, an IgG-Fc-RBD Fusion Protein Next Generation SARS-CoV-2 Booster Vaccine, Via Intranasal and Intramuscular Routes in Previously Vaccinated Adults

This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of Boost-2867, given intramuscular (IM) with or without adjuvant or intranasal (IN) without adjuvant, as a booster dose to previously vaccinated healthy adults. Each of the study sites will be assigned to enroll either only participants who will receive IM administration (up to 5 sites) or only participants who will receive IN administration (up to 5 sites); no site will administer both IM and IN study product administrations. Within the IM and IN Arms the cohorts will be sequentially enrolled. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating one dose level of Boost-2867 without adjuvant administered IM, three dose levels of Boost-2867 with adjuvant administered IM, and three dose levels of Boost-2867 without adjuvant administered IN. A sample size of 140 participants (20 participants per dose cohort) is anticipated. To evaluate for early safety signals for this first-in-human trial, study product administration of participants enrolled for IM administration and those enrolled for IN administration will proceed in a staged fashion. For Cohorts 1 (IM administration without adjuvant) and 5 (IN administration), which may be enrolled and dosed concurrently, 3 sentinel participants under 50 years of age will be enrolled in each Cohort over at least 2 days. For each of those Cohorts independently, a safety review of halting rules and clinical safety data through at least Day 8 will be conducted by the Protocol Safety Review Team (PSRT) prior to enrollment of the remainder of the cohort. Enrollment, dosing, and safety oversight for IM Cohorts 2, 3, and 4 will proceed in the same fashion as Cohort 1, except that sentinel enrollment need not be spaced over at least 2 days. Similarly, for IN Cohorts 6 and 7, enrollment and safety oversight will proceed in the same fashion as Cohort 5, except that sentinel enrollment need not be spaced over at least 2 days.
The primary objectives are: 1) To evaluate the safety and reactogenicity of a single IM injection of three different antigen dose levels (5, 15, and 50 microgram) of Boost-2867 with Alhydrogel (R) (alum) and CpG 7909 adjuvants, and a single injection of 50 microgram Boost-2867 without adjuvant, in previously vaccinated healthy adults. 2) To evaluate the safety and reactogenicity of a single IN administration of three different antigen dose levels (20, 50, and 125 microgram) of Boost-2867 without adjuvant in previously vaccinated healthy adults.

Start Date05 Dec 2025

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

ChiCTR2000036023

/ Not yet recruitingEarly Phase 1IIT

Combined treatment of thermal ablation and CpG 7909/Pembrolizumab for colorectal liver metastases

Start Date01 Sep 2020

Sponsor / Collaborator

Shanghai No. 10 People's Hospital

JPRN-jRCTs061180034

/ CompletedPhase 1IIT

A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer - A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer

Start Date17 May 2016

Sponsor / Collaborator-

100 Clinical Results associated with Agatolimod

100 Translational Medicine associated with Agatolimod

100 Patents (Medical) associated with Agatolimod

1,129

Literatures (Medical) associated with Agatolimod

01 May 2026·POULTRY SCIENCE

Comparative evaluation of a novel phytochemical mixture and monensin on host- and pathogen-targeted strategies in broiler chickens challenged with Eimeria maxima

Article

Author: Lillehoj, Hyun S ; Wall, Emma H ; Ravichandran, Sripathy ; Nam, Hyoyoun ; Park, Inkyung

To unravel the differences between host- and pathogen-mediated responses, this study compared the efficacy and mechanisms of a novel phytochemical mixture and monensin in enhancing growth performance, intestinal health, and modulating gut microbiota in broiler chickens infected with Eimeria maxima (E. maxima). A total of 280 one-day-old male broiler chickens were randomly assigned using a randomized complete block design based on initial body weight (BW) and distributed into four dietary treatments with five chickens per cage: non-challenged control (NC), challenged control (PC), monensin-supplemented (MO), and phytochemical mixture (CPG)-supplemented groups. All chickens, except those in NC, were orally challenged with 10,000 E. maxima oocysts on day 15, and body weights were recorded on days 1, 8, 15, 21, and 23. Fourteen chickens per treatment were euthanized at 6 and 8 days post-infection for jejunal mucosa collection to analyze gene expression of cytokines, tight junction proteins (TJPs), nutrient transporters, TLR4 signaling, and antioxidant enzymes. Jejunal lesion scores, fecal oocyst shedding, and microbial composition were also assessed. Compared with the PC group, supplementation with both MO and CPG significantly reduced jejunal lesion scores and fecal oocyst shedding; however, the magnitude of reduction was greater with MO, resulting in more pronounced improvements in BW and feed conversion ratio. In E. maxima-infected broiler chickens, both treatments alleviated jejunal inflammation by modulating pro-inflammatory cytokine expression and TLR4 signaling; however, CPG was more actively involved in host-mediated responses through restoration of nutrient transporter and TJPs expression, maintenance of intestinal barrier integrity, and enhancement of antioxidant defenses. In contrast, MO acted more effectively on pathogen-related outcomes, such as reductions in oocyst shedding and lesion severity, and also induced distinct alterations in the jejunal microbiota based on microbial community and PICRUSt-based predictive functional analyses. Collectively, this study demonstrates that CPG contributes to the control of E. maxima infection in broiler chickens by simultaneously supporting host intestinal function and gut microbial balance through a mode of action distinct from the pathogen-targeted strategy of monensin.

02 Mar 2026·MOLECULAR PHARMACEUTICS

Overcoming Challenges in Dengue Vaccine Development: Advanced Delivery Approaches

Review

Author: Bhattacharyya, Jayanta ; Sengupta, Anindita

Dengue virus (DENV), comprising four antigenically distinct serotypes, remains a major global health problem. Vaccine development is hindered by immunological barriers, including antibody-dependent enhancement (ADE), original antigenic sin, and the requirement for balanced, long-lasting immunity against all serotypes. This review focuses on emerging strategies that improve vaccine-induced immune memory through rational antigen design and advanced delivery systems. Nanoparticles, including lipid-based carriers, polymeric particles, and virus-like particles (VLPs), support antigen stability, promote dendritic cell (DC) uptake, and enhance delivery to the lymph node. Injectable hydrogels and responsive biomaterials provide sustained antigen release, promoting germinal center (GC) formation and memory B and T-cell memory responses. Targeted delivery using ligands for C-type lectins or mannose receptors further increases the antigen presentation efficiency. Potent adjuvants, including toll- like receptor (TLR) agonists (Poly I:C, CpG, and R848) and saponin-based molecules (QS-21, MPL), activate innate immune sensors and guide Th1-type adaptive responses. New vaccine formulations, including multiepitope peptide vaccines, mRNA and DNA constructs, and extracellular vesicle (EV)-based carriers derived from DCs or milk, offer cell-free, scalable, and immune system-activating platforms. Furthermore, in silico approaches facilitate epitope identification, MHC-binding prediction, and immune response simulation. Collectively, these strategies address recent challenges and support the development of dengue vaccines that offer enhanced safety and durable immunity.

24 Feb 2026·LANGMUIR

Preservative Kinetics and Influence of Surfactants on Gram-Negative Bacterial Membrane Partitioning

Article

Author: Vaiwala, Rakesh ; Chockalingam, Rajalakshmi ; Ayappa, K. Ganapathy ; Patil, Nivedita

Preservatives are primarily used for their antimicrobial properties and form an important component of food, cosmetic, and drug formulations. The efficacy of preservatives depends on various factors, which include the bacterial membrane composition and the interaction between components of a specific formulation. Molecules such as phenoxyethanol (POE), caprylylglycol (CPG), and methylparaben (MEP) are widely used as preservatives in the food and cosmetic industries; however, a molecular understanding of their interactions with surfactants and the kinetics of membrane partitioning remains unexplored. In this study, coarse-grained molecular dynamics simulations were carried out to evaluate and quantify the kinetics of membrane partitioning for preservatives and surfactants in the Escherichia coli inner phospholipid membrane. We propose a mass-transfer-based model to determine membrane partitioning kinetics. Faster kinetics were observed for first-order partitioning of POE and MEP (τ ∼ 0.01 μs) when compared with zeroth-order kinetics (τ ∼ 0.1 μs) for CPG. In contrast, surfactants such as sodium laureth sulfate (SLES) and cocamidopropyl betaine (CAPB) follow zeroth-order membrane partitioning kinetics with significantly higher time constants (1.5-10 μs). Interestingly, zeroth-order kinetics occurred when micellar aggregates were present, and the rate-controlling step was the slow rate of release of single molecules from the aggregate, in comparison to faster membrane uptake kinetics. Using a sequential micellar breakup model with single surfactant release dynamics, we analytically recover this unique zeroth-order membrane partitioning kinetics. In preservative-surfactant mixtures, the kinetics of preservative partitioning were found to decrease by a factor of 2-10. Significantly, the equilibrium membrane saturation coefficients for both preservatives and surfactant remained invariant in the mixtures due to the wide separation of partitioning time scales for the surfactants and preservatives. The kinetic models developed in this study can be used to quantify membrane partitioning of preservatives and understand the influence of surfactants in specific formulations.

News (Medical) associated with Agatolimod

22 Oct 2025

·www.prnewswire.com

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM's proprietary polymersome platform through a strategic collaboration with the National Cancer Centre Singapore (NCCS). Preclinical experiments show that the ACM nanoparticle formulation fundamentally alters CpG's mechanism of action, enabling myeloid modulation through comprehensive TLR9 engagement in immunologically "cold" tumors. The ongoing Phase 1 trial (NCT06587295) [i] is enrolling patients with advanced solid tumors at NCCS to assess the safety, tolerability, and pharmacodynamic effects of ACM-CpG. Early clinical data indicate that these preclinical findings are translating into humans. In patients with advanced solid tumors, intramuscular administration of ACM-CpG - at weekly or biweekly doses as low as 0.25mg CpG – has demonstrated robust systemic immune activation as evidenced through immune biomarker data. The therapy shows a highly favorable safety and tolerability profile and to date, no dose-limiting toxicities have been observed. "TLR9 has long been recognized as a validated immunologic target, but its therapeutic potential has been limited by delivery and safety limitations," said Dr. Madhavan Nallani, CEO of ACM Biolabs. "Our intramuscular nanoparticle delivery enables systemic immune activation with an excellent safety profile, creating opportunities not only for combination approaches but also for targeted monotherapy in patient populations with few treatment options. Over time, this platform can also support additional routes of administration allowing us to tailor treatment strategies to diverse tumor settings and address significant unmet medical needs." "The safety profile and clear pharmacodynamic activity we have observed so far are very encouraging, with two out of the three patients enrolled at the 0.25mg dose level having ongoing disease control for eight months with monotherapy alone." said Dr. Amit Jain, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. "We look forward to exploring ways to optimize its delivery and maximize its therapeutic potential for patients with advanced cancers." The collaboration is supported in part by funding from Singapore's Industry Alignment Fund – Pre-Positioning (IAF-PP), which fosters strategic collaborations between industry and research institutes. This study is evaluating ACM-CpG in patients with advanced head and neck, lung, bladder, and kidney cancers and is designed to establish proof of mechanism to support global clinical development. About ACM Biolabs Pte Ltd ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company's pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. SOURCE ACM Biolabs WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyPhase 1

22 Oct 2025

·acmbiolabs.com

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

Singapore, 22nd October 2025 – ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM’s proprietary polymersome platform through a strategic collaboration with the National Cancer Centre Singapore (NCCS). Preclinical experiments show that the ACM nanoparticle formulation fundamentally alters CpG’s mechanism of action, enabling myeloid modulation through comprehensive TLR9 engagement in immunologically “cold” tumors. The ongoing Phase 1 trial (NCT06587295)i is enrolling patients with advanced solid tumors at NCCS to assess the safety, tolerability, and pharmacodynamic effects of ACM-CpG. Early clinical data indicate that these preclinical findings are translating into humans. In patients with advanced solid tumors, intramuscular administration of ACM-CpG – at weekly or biweekly doses as low as 0.25mg CpG – has demonstrated robust systemic immune activation as evidenced through immune biomarker data. The therapy shows a highly favorable safety and tolerability profile and to date, no dose-limiting toxicities have been observed. “TLR9 has long been recognized as a validated immunologic target, but its therapeutic potential has been limited by delivery and safety limitations,” said Dr. Madhavan Nallani, CEO of ACM Biolabs. “Our intramuscular nanoparticle delivery enables systemic immune activation with an excellent safety profile, creating opportunities not only for combination approaches but also for targeted monotherapy in patient populations with few treatment options. Over time, this platform can also support additional routes of administration allowing us to tailor treatment strategies to diverse tumor settings and address significant unmet medical needs.” “TLR9 has long been recognized as a validated immunologic target, but its therapeutic potential has been limited by delivery and safety limitations,” said Dr. Madhavan Nallani, CEO of ACM Biolabs. “Our intramuscular nanoparticle delivery enables systemic immune activation with an excellent safety profile, creating opportunities not only for combination approaches but also for targeted monotherapy in patient populations with few treatment options. Over time, this platform can also support additional routes of administration allowing us to tailor treatment strategies to diverse tumor settings and address significant unmet medical needs.” “The safety profile and clear pharmacodynamic activity we have observed so far are very encouraging, with two out of the three patients enrolled at the 0.25mg dose level having ongoing disease control for eight months with monotherapy alone.” said Dr. Amit Jain, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. “We look forward to exploring ways to optimize its delivery and maximize its therapeutic potential for patients with advanced cancers.” “The safety profile and clear pharmacodynamic activity we have observed so far are very encouraging, with two out of the three patients enrolled at the 0.25mg dose level having ongoing disease control for eight months with monotherapy alone.” said Dr. Amit Jain, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. “We look forward to exploring ways to optimize its delivery and maximize its therapeutic potential for patients with advanced cancers.” The collaboration is supported in part by funding from Singapore’s Industry Alignment Fund – Pre-Positioning (IAF-PP), which fosters strategic collaborations between industry and research institutes. This study is evaluating ACM-CpG in patients with advanced head and neck, lung, bladder, and kidney cancers and is designed to establish proof of mechanism to support global clinical development. About ACM Biolabs Pte Ltd ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company’s pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. Media contacts Dr Peter Moran Email: peter.moran@acmbiolabs.com General Inquiries: BD@acmbiolabs.com About ACM Biolabs Pte Ltd ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company’s pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. Media contacts Dr Peter Moran Email: peter.moran@acmbiolabs.com General Inquiries: BD@acmbiolabs.com ACM Biolabs is headquartered in Singapore, with subsidiaries in Basel, Switzerland, and Sydney, Australia. It is a clinical-stage biotechnology company developing targeted vaccines and immunotherapies using its proprietary polymer-lipid hybrid nanoparticle delivery platform. The company’s pipeline includes candidates across oncology, infectious diseases, and inflammation, with a focus on precision immune modulation and next-generation drug delivery. Media contacts Dr Peter Moran Email: peter.moran@acmbiolabs.com General Inquiries: BD@acmbiolabs.com 1 https://www.clinicaltrials.gov/study/NCT06587295

ImmunotherapyPhase 1

28 Aug 2025

·liddspharma.com

LIDDS AB (publ) Interim Report January – June 2025

April – June 2025 Net sales amounted to 0 (0) KSEK The operating result for the period was -836 (-2 391) KSEK The net result was -733 (-2 398) KSEK corresponding to earnings per share of -0,01 (-0.02) SEK Cash flow from operating activities amounted to -1 594 (-2 938) KSEK Cash and cash equivalents amounted to 2 350 (8 009) KSEK January – June 2025 Net sales amounted to 0 (0) KSEK The operating result for the period was -2 091 (-2 392) KSEK The net result was -2 044 (-2 404) KSEK corresponding to earnings per share of -0,01 (-0.02) SEK Cash flow from operating activities amounted to -2 333 (-3 002) KSEK Significant events January – June 2025 On April 2, the board of directors decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202. Taking into account the principle of prudence, the board of directors, decided on April 10 to write down the book values of all intangible assets in LIDDS and Noviga as of 2024-12-31. This decision resulted in a deviation for the annual report compared to the published year-end report for 2024. Due to the reasons to believe that the company’s equity was less than on-half of the registered share capital, the board of directors decided to prepare a balance sheet for liquidation purpose on April 22. The balance sheet for liquidation purpose prepared and reviewed by the company’s auditor showed that the equity was less than half of the registered share capital and therefore the board of directors decided on April 24 to call a first control meeting. At the annual general meeting, at the same time first control meeting, on May 28, it was decided that the company will continue its operations and not be liquidated. CEO Statement During the second quarter, the company has continued to focus on the commercialisation of the three projects Nanoimod, Nanodotax and NOV 202, as well as exploring interest in the company’s listing on First North. So far, these efforts have not yet resulted in any concrete successes. The quarter has also been characterised by extensive work on finalising the annual report, holding the annual general meeting, and managing the situation where the company’s equity was found to be less than half of the share capital. Following the decision at the first control meeting to continue operations and not initiate liquidation, the company now has eight months before the question of potential liquidation needs to be reconsidered. Mats WikingCEO and CFO The interim report is available on the company’s website https://liddspharma.com/en/investors/financial-reports/ For additional information, please contact Mats Wiking, CEO and CFOPhone: +46 (0)70 620 04 00E-mail: mats.wiking@liddspharma.com Daniel Lifveredson, Chairman of the BoardTelefon: +46 (0) 70-916 21 01Email: d.li@excore.com LIDDS’ Certified Adviser is Redeye AB LIDDS in brief: LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market. Attachments LIDDS Interim Report Q2 2025

Financial Statement

100 Deals associated with Agatolimod

External Link

KEGG	Wiki	ATC	Drug Bank
D08841	Agatolimod	-	DB15018

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
metastatic non-small cell lung cancer	Phase 3	Italy	Pfizer Inc.	20 Jun 2006
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 3	Hungary	Pfizer Inc.	19 Jan 2006
Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Australia	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Austria	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Belgium	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Brazil	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Canada	Pfizer Inc.	01 Nov 2005
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Cyprus	Pfizer Inc.	01 Nov 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00199836 (CTgov)	Phase 1	Neoplasms	14	NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51	ytxfnpphuh = hipfxomjwb ecbsybtfix (znxjpmfmwn, ieqyrqfuqp - lttenthkvh) View more	-	15 Jul 2021
AACR2017	Phase 2	Melanoma Adjuvant	-	Saline	hfyzqhtnzo(psloenjgpf) = nxzpyggyfc lljyeiivyp (chtmmclbgx, 21 - 71)	Positive	01 Jul 2017
NCT00880581 (CTgov)	Phase 2	Indolent B-Cell Non-Hodgkin Lymphoma	30	Local radiotherapy+PF-3512676	khehhbjrax = zsvhccpgrv bcyybaerqb (qratfvgyhx, wztcbxwlea - ysyesujxam) View more	-	14 Mar 2017
NCT00824733 (CTgov)	Phase 2	Locally advanced breast cancer \| Metastatic breast cancer	6	Correlative Studies+PF03512676+Trastuzumab	enrakcvjzw(nftldqjhad) = qnfflsrasw yzgxgzstrc (petfjvtvlg, svlaqdskqq - bbfvhxjivz) View more	-	14 Jan 2016
SITC2015	Phase 2	Melanoma Adjuvant	62	GM-CSF (3 μg/kg)	ztpulbsyab(yvqxjlbfat) = at a median follow-up of 79 months, this translated into a significantly longer recurrence-free survival (RFS) in the CpG-treated group (p=0.010) yzazsuetlx (oisjyzifqf )	Positive	04 Nov 2015
SITC2015	Phase 2	Melanoma Adjuvant	62	CpG-B (PF-3512676/CpG7909, 8 mg)		Positive	04 Nov 2015
NCT00185965 (CTgov)	Phase 1/2	Mycosis Fungoides	30	CPG 7909 (Lymphoma, B-cell Low-grade (BCL))	pyyzhfrfrt = teqbbksmhu emjtfjgbjb (ayhwnyaltg, ekdsxnngfk - lvidrhjfsx) View more	-	01 Aug 2014
NCT00185965 (CTgov)	Phase 1/2	Mycosis Fungoides	30	CPG 7909 (Mycosis Fungoides (MF))	pyyzhfrfrt = zbnxsvtzkj emjtfjgbjb (ayhwnyaltg, qumfdannjj - kfnxbvbvip) View more	-	01 Aug 2014
Pubmed \| J Immunother	Phase 1	Metastatic melanoma Adjuvant	22	Vaccination with MART-1, gp100, and Tyrosinase peptides + PF-3512676 + GM-CSF	njwkdbsqji(jdavagewfh) = fnmtfhemph ssodohxgcw (nevqqfxgni, 11.3 - ∞)	-	01 May 2012
NCT00984763 (Pubmed \| PLoS One)	Phase 1	Malaria	5	AMA1-C1/Alhydrogel+CPG 7909 (AMA1/C1-Alhydrogel+CPG 7909)	dypqnnxlud(fpsdojrvsl): Pearson r = -0.93 (95% CI, -0.99 to -0.25), P-Value = 0.02	-	22 Jul 2011
NCT00984763 (Pubmed \| PLoS One)	Phase 1	Malaria	5	AMA1-C1/Alhydrogel+CPG 7909 (Unvaccinated controls)		-	22 Jul 2011
AACR2011	Not Applicable	Melanoma	12	Vaccination with MART-1 (27-35), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) peptides given in-oil-adjuvant with TLR-9 agonist PF-3512676 and GMCSF	zkisbxfzxt(wotwbxfuqg) = kpklxhxkey cpjyhddxuc (qbbpvsjcsy ) View more	-	15 Apr 2011
Pubmed \| J Am Acad Dermatol	Phase 1	Cutaneous T-Cell Lymphoma	28	PF-3512676 (CPG 7909)	xzjsdiuhsu(thtxpknaid) = qyaythypwy vcleggrrtv (cyotoqcujj )	Positive	01 Dec 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Agatolimod

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation